Naveglitazar

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319623

CAS#: 476436-68-7

Description: Naveglitazar, also known as LY 519818, LY 9818, is a peroxisome proliferator-activated receptor (PPAR) modulator, had been in phase II clinical trials for the once-daily oral treatment of type 2 diabetes, however, no recent development for this indication has been reported.


Price and Availability

Size
Price

10mg
Not available
100mg
Not available
1g
Ask price
10g
Ask price
Size
Price

25mg
Not available
200mg
Not available
2g
Ask price
20g
Ask price
Size
Price

50mg
Not available
500mg
Not available
5g
Ask price
50g
Ask price

Naveglitazar is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 319623
Name: Naveglitazar
CAS#: 476436-68-7
Chemical Formula: C25H26O6
Exact Mass: 422.1729
Molecular Weight: 422.477
Elemental Analysis: C, 71.07; H, 6.20; O, 22.72


Synonym: LY519818; LY-519818; LY 519818; LY-9818; LY9818; LY 9818; CCRIS 9448; Naveglitazar.

IUPAC/Chemical Name: (S)-2-methoxy-3-(4-(3-(4-phenoxyphenoxy)propoxy)phenyl)propanoic acid

InChi Key: OKJHGOPITGTTIM-DEOSSOPVSA-N

InChi Code: InChI=1S/C25H26O6/c1-28-24(25(26)27)18-19-8-10-20(11-9-19)29-16-5-17-30-21-12-14-23(15-13-21)31-22-6-3-2-4-7-22/h2-4,6-15,24H,5,16-18H2,1H3,(H,26,27)/t24-/m0/s1

SMILES Code: O=C(O)[C@@H](OC)CC1=CC=C(OCCCOC2=CC=C(OC3=CC=CC=C3)C=C2)C=C1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Tseng CH, Tseng FH. Peroxisome proliferator-activated receptor agonists and
bladder cancer: lessons from animal studies. J Environ Sci Health C Environ
Carcinog Ecotoxicol Rev. 2012;30(4):368-402. doi: 10.1080/10590501.2012.735519.
Review. PubMed PMID: 23167631.

2: Long GG, Reynolds VL, Dochterman LW, Ryan TE. Neoplastic and non-neoplastic
changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR
alpha/gamma agonist. Toxicol Pathol. 2009 Oct;37(6):741-53. doi:
10.1177/0192623309343775. Epub 2009 Aug 21. PubMed PMID: 19700659.

3: Ahlawat P, Srinivas NR. Allometric prediction of the human pharmacokinetic
parameters for naveglitazar. Eur J Drug Metab Pharmacokinet. 2008
Jul-Sep;33(3):187-90. PubMed PMID: 19007045.

4: Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR.
Urothelial carcinogenesis in the urinary bladder of rats treated with
naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for
urolithiasis as an inciting event. Toxicol Pathol. 2008 Feb;36(2):218-31. doi:
10.1177/0192623307311757. PubMed PMID: 18474944.

5: Yi P, Hadden CE, Annes WF, Jackson DA, Peterson BC, Gillespie TA, Johnson JT.
The disposition and metabolism of naveglitazar, a peroxisome
proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice,
rats, and monkeys. Drug Metab Dispos. 2007 Jan;35(1):51-61. Epub 2006 Sep 29.
PubMed PMID: 17012539.